Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tumor Characteristics Associated With Preoperatively Detectable Tumor-Informed Circulating Tumor DNA in Patients With Renal Masses Suspicious for Renal Cell Carcinoma.
Ben-David R, Alerasool P, Kalola H, Tillu N, Almoflihi M, Tsao CK, Galsky MD, Sfakianos JP, Wiklund P, Waingankar N, Mehrazin R. Ben-David R, et al. Among authors: alerasool p. JCO Precis Oncol. 2024 Sep;8:e2400281. doi: 10.1200/PO.24.00281. Epub 2024 Sep 30. JCO Precis Oncol. 2024. PMID: 39348609
Comparative Effectiveness of Bacillus Calmette-Guérin and Sequential Intravesical Gemcitabine and Docetaxel for Treatment-naïve Intermediate-risk Non-muscle-invasive Bladder Cancer.
Kolanukuduru KP, Ben-David R, Lidagoster S, Almoflihi M, Tillu N, Eraky A, Alerasool P, Waigankar N, Attalla K, Mehrazin R, Wiklund P, Sfakianos JP. Kolanukuduru KP, et al. Among authors: alerasool p. Eur Urol Focus. 2024 Sep 20:S2405-4569(24)00173-1. doi: 10.1016/j.euf.2024.09.006. Online ahead of print. Eur Urol Focus. 2024. PMID: 39306526
Induction and maintenance of sequential intravesical gemcitabine/docetaxel for intermediate and high-risk non-muscle invasive bladder cancer with different dosage protocols.
Ben-David R, Tillu N, Alerasool P, Bieber C, Ranti D, Tolani S, Eisenhauer J, Chung R, Lavallée E, Waingankar N, Attalla K, Wiklund P, Mehrazin R, Anderson CB, Sfakianos JP. Ben-David R, et al. Among authors: alerasool p. World J Urol. 2024 May 11;42(1):315. doi: 10.1007/s00345-024-04992-5. World J Urol. 2024. PMID: 38734774
The role of preoperative immune cell metrics in renal cell carcinoma with a tumor thrombus.
Sandberg M, Namugosa M, Ritts R, Costa CM, Temple D, Hayes M, Whitman W, Ye E, Refugia J, Ben-David R, Alerasool P, Eilender B, Zanotti RR, Mourão TC, Kim JK, Marchiñena PG, Byun SS, Abreu D, Mehrazin R, Spiess P, de Cassio Zequi S, Rodriguez A. Sandberg M, et al. Among authors: alerasool p. Urologia. 2024 Aug;91(3):477-485. doi: 10.1177/03915603241248020. Epub 2024 Apr 25. Urologia. 2024. PMID: 38661082
Active Compared With Passive Voiding Trials After Midurethral Sling Surgery: A Systematic Review.
Drangsholt S, Lleras C, Kindler R, Babajanian M, Pollack B, Harutyunyan A, Grunfeld M, Gejerman Y, Kilkenny K, Bulmash M, Hirani R, Alerasool P, McNeil C, Popiel P, Drugge ED, Grimes C. Drangsholt S, et al. Among authors: alerasool p. Obstet Gynecol. 2024 May 1;143(5):633-643. doi: 10.1097/AOG.0000000000005567. Epub 2024 Mar 28. Obstet Gynecol. 2024. PMID: 38547487
17 results